Mylan and development partner win significant EPO ruling related to Copaxone

Decision clears legal pathway to expand access for patients living with multiple sclerosis in markets across Europe.
The Technical Board of Appeal of the European Patent Office (EPO) has held that Yeda Research and Development Company, Ltd.'s European Patent no. 2 949 335 related to Teva's Copaxone 40 mg/mL three times weekly product is invalid and revoked across Europe.
With the EPO's decision, Mylan has once again overcome Teva's attempts to restrict multiple sclerosis (MS) patients' access to safe and affordable alternatives.
During the last 11 years, Mylan has successfully defeated Teva's four waves of US patent litigation, eight Citizen Petitions, injunction proceedings in India, and more than 15 regulatory challenges, patent litigations or commercial actions across Europe.
The EPO's positive ruling will allow Mylan to immediately return to the market and accelerate commercialization in other markets across Europe.
Mylan CEO Heather Bresch commented: "The decision by the EPO marks a significant step forward for Mylan in several ongoing legal actions around Europe related to this important product, and further increases our confidence in our ability to continue to expand access to a lower-cost, high quality, therapeutically equivalent version of Copaxone to the multiple sclerosis community across even more markets in Europe and beyond."
Indicated for the treatment of patients with relapsing forms of MS, Mylan's lower-cost therapeutically equivalent version of Copaxone will benefit thousands of MS patients across Europe who are living with this very difficult condition and in need of a more affordable treatment option.
Mylan's product is currently marketed under a number of brand names in European markets including Brabio, Clift, Copemyl, Copemyltri and Glatiramyl.

Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Investors turn attention to biotechs with clear path to market
Companies that are further down the road to market are more attractive to investors than those in early development -
News Tonix strives for pandemic readiness with new US manufacturing facility
The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat -
News Valneva stock jumps as Pfizer invests more than €90M to support Lyme disease vaccine trial
VLA15 is the only Lyme disease vaccine candidate currently in clinical development -
News Niche start-ups spearheading cell and gene therapy innovation
Smaller companies targeting rare and extremely specific treatment areas are leading the charge in this emerging market. -
News GSK to acquire clinical-stage biopharma company Affinivax
The $3.3 billion deal will strengthen GSK’s vaccine pipeline. -
News Samsung Biologics fully acquires Samsung Bioepis for $2.3B
Samsung Biologics has full ownership over Samsung Bioepis after purchasing Biogen’s stake -
News Thermo Fisher opens $44M bioprocessing manufacturing site in Utah
The site will produce customisable bioprocess container systems.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance